

Table SII. Detailed overview of interventional study characterizing the gut microbiome in patients with psoriasis after treatment with probiotics vs placebo

Study/outcome	Author (year)	Study type	Sample Type/kit	Study population	Intervention/objective	Method	Main findings	Additional notes
Interventional studies	Gut microbiology Navarro-Lopez (2019) Spain (34)	Double-blinded randomized-controlled trial	Stool/ Immediately frozen/ stored at -80°C	Psoriasis, probiotic, $n=46$ Psoriasis, placebo, $n=44$ Baseline PASI: Mean \pm SD 11.7 (5.1)/11.5 (4.2)	No systemic (biologic, methotrexate cyclosporine) treatment 3 months prior to study start No systemic antibiotics 2 weeks prior to study start Probiotics	16sRNA (V3-V4), Illumina Miseq Sequencing	Baseline enterotype (higher presence of) 1 Bacteroides 2 Prevotella 3 Ruminococcus No statistically significant change in any of the enterotypes. No significance in Shannon diversity between probiotic/placebo groups. Total disappearance of the genera <i>Micromonospora</i> , <i>Rhodococcus</i> , increase in <i>Collinsella</i> and <i>Lactobacillus</i> in probiotic group PASI75 week 12 Probiotic: 66.7% Placebo: 41.9%	Topical treatment allowed during the study and amount of use of topical treatment not registered.